Asclepii转发了
#Cleveland biotech startup Asclepii is bridging the gap between Band-Aids and $30,000 wound care. Discover its innovative solution. #biotech
Asclepii
医疗设备制造业
Cleveland，OH 323 位关注者
Next-Gen Regen Med From the lab of the creator of the world's first cell therapy, to cell therapy all over the world.
关于我们
US-Based Medical Device company focused on Regenerative Medicine in the wound healing niche. An international healthcare technology designer and manufacturer, Asclepii strives to tackle challenging health problems facing humanity with innovations that accessibly transform lives.
- 网站
-
asclepii.com
Asclepii的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 11-50 人
- 总部
- Cleveland，OH
- 类型
- 私人持股
- 创立
- 2022
- 领域
- Medical Devices、Wound healing、Drug delivery、Stem Cells和MedTech
地点
-
主要
获取路线
US，OH，Cleveland，44106
Asclepii员工
-
Daniel Katzman
-
Santiago Kraiselburd
Vice Rector of Research @ Tec de Monterrey | 3x Founder | CEO | Board Member | President | Over US$ 2 MM non-dilutive raised in Co-Founded Startups |…
-
Franco Kraiselburd
Founder & CEO @ Asclepii | MIT Innovator Under 35 | MIT IU35 Pioneer of the Year (2024) | LA NACION (Arg) 24 people of 2024
-
Brian Kratt
Masters Student at Case Western Reserve - Regenerative Medicine and Entrepreneurship
动态
-
Thank you to the Cleveland Business Journal for featuring Asclepii’s major recent milestone of securing VC backing from Zentynel Frontier Investments!
#Cleveland biotech startup Asclepii is bridging the gap between Band-Aids and $30,000 wound care. Discover its innovative solution. #biotech
-
Asclepii转发了
#Cleveland biotech startup Asclepii is bridging the gap between Band-Aids and $30,000 wound care. Discover its innovative solution. #biotech
-
Asclepii转发了
Founder & CEO @ Asclepii | MIT Innovator Under 35 | MIT IU35 Pioneer of the Year (2024) | LA NACION (Arg) 24 people of 2024
I’d like to announce that Asclepii just received its first VC backing! When I thought of the top VCs in the world and who I’d like to invest in our round, Zentynel Frontier Investments was top of mind. Their legendary history paired with a spectacular track record both scientifically and entrepreneurially meant they’d be a perfect fit to lead our company into new horizons. Then I met Cristian Hernandez-Cuevas and Martha Laura L., true visionaries, and I realized I was completely wrong. New horizons doesn’t even begin to cut it. The direction we’re headed is incredibly exciting and aggressive. BEYOND what we imagined! We’re honored to have institutions like Zentynel who believe in Artemis, Asclepii’s team, and our potential. With their prior experiences in Wound Care and DeepTech, Cristián and Martha Laura opened our minds to creative and strategic lenses of sophistication. We started achieving a deeper understanding of the market’s incumbents, improving our Go-To-Market significantly. It’s gratifying to see the Asclepii vision culminating into relentless execution! THANK YOU to our amazing team and supporters who made this a reality!! Miguel Fuentes Chandia Santiago Kraiselburd Daniel Katzman Ixchel Robles Ruiz William Tavel Kirsten Tysl Victorina Fischenich Lawrence Pratt Robin Wiscovitch Agustin Büchert Mark Terzola Nate Haskell Luis Martinez Peter Gingras Robert Priest, PE, PMP PBW BioLOGICA Leonard & Terzola Co., Ltd Project Medtech Viscus Biologics LLC Capital Factory JumpStart Inc. Also thank you to Case Western Reserve University’s CWRU Veale Institute for Entrepreneurship team as well :) Michael Goldberg Tiffany Cashon Mindy Baierl Stacey Lotz Megan Kuhar Brittain Elswick And to Jeffrey Stern Marina Jackman Beno Oppenheimer Guillermo Ulises Ruiz-Esparza MD, PhD, FRSA Francisco Valencia Luis Stein
Zentynel Frontier Investments invierte en Asclepii para transformar el tratamiento de heridas crónicas Las heridas crónicas afectan a más de 50 millones de personas en el mundo, prolongando hospitalizaciones y reduciendo la calidad de vida de los pacientes. Su tratamiento puede superar los US $45 mil por persona, representando una enorme carga para los sistemas de salud. Asclepii está transformando el cuidado de heridas con Artemis, un apósito avanzado —un material dise?ado para proteger y favorecer la cicatrización— que combina un andamiaje semi-sintético con un sistema de liberación de fármacos para acelerar la recuperación y prevenir infecciones. Su tecnología reduce significativamente los tiempos de sanación y costos, haciendo los tratamientos más eficientes y accesibles. Con un mercado proyectado en US $9.1 mil millones para 2025, Asclepii está posicionada para liderar este sector con su plataforma innovadora. En Zentynel Frontier Investments, invertimos en empresas que no solo innovan, sino que transforman vidas y amplían el acceso a la salud.
-
-
We're excited to announce the Lead investor for our $2 MM Seed round - Zentynel Frontier Investments! Incredible traction from our team as we advance to the next stages. Stay tuned as we announce more updates at SXSW. We'll also be all over Capital Factory House! A great way to kick off #SXSW. Partners & Supporters: Viscus Biologics LLC Project Medtech Case Western Reserve University JumpStart Inc. Leonard & Terzola Co., Ltd PBW BioLOGICA Capital Factory Zentynel Frontier Investments Midwest House SXSW Hult Prize Foundation Lay of The Land Podcast #Investor #Fundraising #Startup #RegenMed #Entrepreneurship
Zentynel Frontier Investments invierte en Asclepii para transformar el tratamiento de heridas crónicas Las heridas crónicas afectan a más de 50 millones de personas en el mundo, prolongando hospitalizaciones y reduciendo la calidad de vida de los pacientes. Su tratamiento puede superar los US $45 mil por persona, representando una enorme carga para los sistemas de salud. Asclepii está transformando el cuidado de heridas con Artemis, un apósito avanzado —un material dise?ado para proteger y favorecer la cicatrización— que combina un andamiaje semi-sintético con un sistema de liberación de fármacos para acelerar la recuperación y prevenir infecciones. Su tecnología reduce significativamente los tiempos de sanación y costos, haciendo los tratamientos más eficientes y accesibles. Con un mercado proyectado en US $9.1 mil millones para 2025, Asclepii está posicionada para liderar este sector con su plataforma innovadora. En Zentynel Frontier Investments, invertimos en empresas que no solo innovan, sino que transforman vidas y amplían el acceso a la salud.
-
-
We're going to #SXSW! Not pitching this time, though :) Capital Factory SXSW Inc. Magazine Midwest House #HyperScale #RegenMed
Founder & CEO @ Asclepii | MIT Innovator Under 35 | MIT IU35 Pioneer of the Year (2024) | LA NACION (Arg) 24 people of 2024
It's the most wonderful time of the year! SXSW 2025 is coming very, very soon... And Asclepii's touring Austin, San Antonio, and Houston from Mar 6th-14th! We'll be pitching at Midwest House as part of the Elite 8, present at Inc. Magazine's Founder's House, and going to several Capital Factory Backstage events including Startup Crawl. Are you in #DeepTech or #RegenMed? Are you passionate about #HyperScale? Are you a #Founder or #Investor heading to #SXSW? Let's meet!! #entrepreneur #funder #pitch
-
-
Asclepii's in the Elite 8 of Midwest House's Midwest Madness Pitch Competition!!! Out of 220 startups, it is an honor to represent #Cleveland and the #NortheastOhio ecosystem at the Midwest Stage. A heartful thank you to Startup Grind Grand Rapids, Ted Velie, and Corey Hart. Come check us out at #midwesthouse #pitchcompetition! See you in Austin, TX Mar 9th. Franco Kraiselburd William Tavel Ixchel Robles Ruiz Victorina Fischenich Santiago Kraiselburd Daniel Katzman Kirsten Tysl Miguel Fuentes Chandia
-
-
Asclepii转发了
Meet Ixchel Robles Ruiz, co-founder of Asclepii. Asclepii is addressing the chronic wound crisis with innovative tissue engineering therapeutics. Their flagship product, Artemis, is a semi-synthetic scaffold designed for easy and painless wound healing. ?? Support Ixchel and the Asclepii team as they present at JumpStart HQ tomorrow during the Startup Showcase! Register here: https://ow.ly/mPUQ50SovKq #HealthTechAccelerator #MeetTheCohort #StartupShowcase